Summary
To define the most effective treatment for polyarteritis nodosa (PAN) and Churg-Strauss syndrome (CSS), we undertook four consecutive prospective therapeutic trials including 244 patients and tried to answer several important questions: should cyclophosphamide (CYC) be given as the first-line treatment? What is the place of plasma exchanges (PE) in the treatment of systemic vasculitis? Does hepatitis B virus (HBV) related PAN require specific treatment?
Our first randomized trial in 71 patients (1981–83) compared the association of CYC with corticosteroids (CS) and PE to CS and PE, in order to evaluate the efficacy of CYC given as the first-line treatment to control disease activity and subsequent survival of PAN and CSS patients. Between December 1983 and December 1988, we conducted two trials simultaneously: one aimed at patients without HBV markers and the second at patients with HBV markers. In 78 patients without HBV markers, we compared prednisone and PE to prednisone al.one as the initial therapeutic regimen. In 33 patients with PAN related to HBV, a new therapeutic strategy was applied as an al.ternative to long-term steroid and immunosuppressive therapy: short-term steroid therapy and PE were used to control the evolution of PAN and antiviral therapy was administered to suppress the etiological agent of the vasculitis. In the last protocol, which included 62 patients and addressed severe PAN without HBV markers or CSS, we showed that PE did not improve the prognosis and control of the disease.
Twelve years after the beginning of the trials on PAN and CSS patients, we think that the therapeutic strategy should be as follows:
-
In PAN without HBV and CSS: Prednisone in association with CYC improves the control of the disease despite infectious side-effects which may be reduced by better CYC dose adaptation.
-
In PAN related to HBV: the first-line treatment should be the association of antiviral agents and PE. This treatment was effective and cured a majority of patients within two to three months; half of them seroconverted. The length of HBV infection before its diagnosis, delay before initiation of treatment and previous immunosuppressive therapy led to a poor seroconversion rate.
-
The role of PE in the treatment of systemic necrotizing vasculitis: PE are obviously useful in PAN related to HBV where immune complex deposition has been demonstrated. When PAN is not related to HBV and in CSS, even in severe cases, there is presently no argument supporting systematic administration of PE at the time of diagnosis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kussmaul, A. and Maier, K. (1866) Über eine bisher nicht beschreibene eigenthümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender al.lgemeiner Muskelhämung einhergeht. Dtsch. Arch. Klin. Med., 1, 484–518.
Frohnert, P. and Sheps, S. (1967) Long term follow-up study of polyarteritis nodosa. Am. J. Med., 48, 8–14.
Leib, E., Restivo, C. and Paulus, H. (1979) Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am. J. Med., 67, 941–7.
Fauci, A., Katz, P., Haynes, B. and Wolff, S. (1979) Cyclophosphamide therapy of severe necrotizing vasculitis. N. Engl. J. Med., 301, 235–8.
Cohen, R., Conn, D. and Ilstrup, D. (1980) Clinical features, prognosis and response to treatment in polyarteritis. Mayo Clin. Proc., 55, 146–55.
Guillevin, L., Tanter, Y., Bletry, O. et al. (1983) Treatment of severe polyarteritis nodosa with plasma exchange. Prog. Artif. Organs, 204, 723–6.
Bletry, O., Bussel, A., Badelon, I. et al. (1982) Intérêt des échanges plasma-tiques au cours des angéites nécrosantes. Onze cas. Nouv. Presse Méd., 11, 2827–32.
Lockwood, C., Rees, A. and Pinching, A. (1977) Plasma exchanges and immunosuppression in the treatment of fulminating immune complex cres-centic nephritis. Lancet, 1, 63–7.
Guillevin, L., Lê, T.H.D., Godeau, P. et al. (1988) Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br. J. Rheumatol., 27, 258–64.
Gocke, D., Hsu, K., Morgan, C. et al. (1970) Association between polyarteritis and Australia antigen. Lancet, 2, 1149–53.
Trepo, C. and Thivolet, J. (1970) Antigen Australia, hépatite à virus et périartérite noueuse. Presse Méd., 78, 1575.
Trepo, C., Ouzan, D., Delmont, J. and Tremisi, P. (1988) Supériorité d’un nouveau traitement curateur des périartérites noueueses induites par le virus de l’hépatite B grâce à l’association corticothérapie brève, vidarabine et échanges plasmatiques. Presse Méd., 17, 1527–31.
Guillevin, L., Lê, T.H.D. and Gayraud, M. (1989) Systemic vasculitis of the polyarteritis nodosa group and infection with hepatitis B virus: a study in 98 patients. Eur. J. Intern. Med., 1, 97–105.
Guillevin, L., Jarrousse, B., Lok, C. et al. (1991) Longterm follow-up after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J. Rheumatol., 18 (4), 567–74.
Guillevin, L., Lhote, F., Leon, A. et al. (1993) Treatment of polyarteritis nodosa related to hepatitis B virus with short-term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J. Rheumatol., 20, 289–98.
Wood, J., Czaja, A., Taswell, H. et al. (1987) Hepatitis B virus desoxyribonu-cleic acid in serum during hepatitis Be antigen clearance in corticosteroid-treated severe chronic active hepatitis B. Gastroentérology, 93, 1225–30.
Arkin, A. (1930) A clinical and pathological study of polyarteritis nodosa. Am. J. Pathol., 6, 401–2.
Bron, K., Strott, C. and Shapiro, A. (1983) The diagnostic value of angiographic observations in polyarteritis nodosa. A case of multiple aneurysms in the visceral organs. Arch. Intern. Med., 116, 450–4.
Chalopin, J., Rifle, G., Turc, J. et al. (1980) Immunological findings during successful treatment of HBs Ag-associated polyarteritis nodosa by plasmapheresis al.one. Br. Med. J., 1, 368.
Guillevin, L., Fain, O., Lhote, F. et al. (1992) Lack of superiority of steroids plus plasma exchange to steroids al.one in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum., 35, 208–15.
Hoffman, G.S., Kerr, G.S., Leavitt, R.Y. et al. (1992) Wegener’s granulomatosis: an analysis of 158 patients. Ann. Intern. Med., 116, 488–98.
Kahn, M., Arlet, J., Bloch-Michel, H. et al. (1979) Leucémies aiguës après traitement par agents cytotoxiques en rhumatologie. 19 observations chez 2006 patients. Presse Méd., 8, 1393–7.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Guillevin, L., Lhote, F. (1996). Treatment of polyarteritis nodosa and Churg-Strauss syndrome. In: Ansell, B.M., Bacon, P.A., Lie, J.T., Yazici, H. (eds) The Vasculitides. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2889-4_24
Download citation
DOI: https://doi.org/10.1007/978-1-4899-2889-4_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-412-64140-4
Online ISBN: 978-1-4899-2889-4
eBook Packages: Springer Book Archive